Evidence map›Paper›PMID 40166258›Full record

ArticlebioRxiv : the preprint server for biology2025

Functional Spectrum of USP7 Pathogenic Variants in Hao-Fountain Syndrome: Insights into the Enzyme's Activity, Stability, and Allosteric Modulation.

Emilie J Korchak, Mona Sharafi, Isabella Jaen Maisonet, Pilar Caro, Christian P Schaaf, Sara J Buhrlage, Irina Bezsonova

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Emilie J KorchakDepartment of Molecular Biology and Biophysics, UCONN Health, Farmington, Connecticut 06032, United States.ORCID 0000-0002-6091-8636
Mona SharafiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Isabella Jaen MaisonetDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.ORCID 0000-0003-4996-3492
Pilar CaroInstitute of Human Genetics, Heidelberg University, Heidelberg, Germany.
Christian P SchaafInstitute of Human Genetics, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-2148-7490
Sara J BuhrlageDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.ORCID 0000-0003-4562-1823
Irina BezsonovaDepartment of Molecular Biology and Biophysics, UCONN Health, Farmington, Connecticut 06032, United States.ORCID 0000-0002-8629-0349

Funding

Cancer Chemical Biology and Metabolism Training ProgramT32CA236754 · NCI · DANA-FARBER CANCER INST · PI Nika N Danial, THOMAS M ROBERTS · 2019 to 2026
$2.6M
UBIQUITIN-PROTEASOME PATHWAY IN CANCERR35GM128864 · NIGMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BEZSONOVA, IRINA · 2018 to 2022
$1.6M
UBIQUITIN-PROTEASOME PATHWAY in HUMAN DISEASER35GM156397 · NIGMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Irina Bezsonova · 2025 to 2026
$1000k
Understanding the effect of Hao-Fountain syndrome-causing mutations on neuronal developmentR21NS135343 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BEZSONOVA, IRINA, O'NEIL, ALISON LINSLEY · 2024 to 2024
$462k
NCI NIH HHS T32 CA236754NIGMS NIH HHS R35 GM128864NIGMS NIH HHS R35 GM156397NINDS NIH HHS R21 NS135343
6 · The paper itself

Abstract

Hao-Fountain syndrome is a rare neurodevelopmental disorder caused by mutations in the de-ubiquitinating enzyme USP7 (Ubiquitin Specific Protease 7). Due to the novelty of the disease and its poorly understood molecular mechanisms, treatments for the syndrome are currently lacking. This study examines the effects of 11 patient-derived variants located within the catalytic domain of USP7, focusing on their impact on the enzyme's activity, thermodynamic stability, and substrate recognition. Our findings reveal a spectrum of functional consequences, ranging from complete inactivation to hyperactivation of USP7. Notably, we identify a specific subset of pathogenic variants whose catalytic activity can be significantly boosted using a novel allosteric activator. These results provide the first insight into USP7 malfunction in Hao-Fountain syndrome-linked variants and pave the way for improved prognostic approaches and targeted treatments in the future.

Indexed as

de-ubiquitinationenzyme activationenzyme kineticsHao-Fountain syndromeneurodevelopmental disorderNMRpathogenic variantspatient mutationsUSP7

Identifiers

PMID40166258
PMCPMC11957113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.